Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:dinucleotide
go back to main search page
Accession:CHEBI:47885 term browser browse the term
Synonyms:related_synonym: Formula=C10H18O13P2R2;   dinucleotides
 alt_id: CHEBI:13207;   CHEBI:23823;   CHEBI:4626
 xref: KEGG:C01910


show annotations for term's descendants           Sort by:
 
FAD term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ndufa9 NADH:ubiquinone oxidoreductase subunit A9 multiple interactions ISO Flavin-Adenine Dinucleotide binds to and results in increased activity of NDUFA9 protein CTD PMID:25526675 NCBI chr 4:159,371,263...159,399,636
Ensembl chr 4:159,371,259...159,399,634
JBrowse link
G Rfk riboflavin kinase increases abundance ISO RFK protein results in increased abundance of Flavin-Adenine Dinucleotide CTD PMID:21308351 NCBI chr 1:236,494,221...236,501,733
Ensembl chr 1:236,494,221...236,501,733
JBrowse link
G Slc52a3 solute carrier family 52 member 3 multiple interactions EXP Flavin-Adenine Dinucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin] CTD PMID:19122205 NCBI chr 3:147,503,266...147,517,935
Ensembl chr 3:147,511,406...147,516,455
JBrowse link
NAD zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acmsd aminocarboxymuconate semialdehyde decarboxylase increases abundance EXP ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr13:44,424,689...44,468,734
Ensembl chr13:44,424,689...44,468,734
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions
increases activity
ISO [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein
CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 multiple interactions ISO [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 5:61,382,351...61,387,359
Ensembl chr 5:61,382,351...61,387,358
JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance
ISO
EXP
[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD
CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 PMID:23295226 NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity
ISO [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein
CTD PMID:10856427 PMID:21256123 NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 multiple interactions EXP NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
JBrowse link
G Arntl aryl hydrocarbon receptor nuclear translocator-like decreases oxidation ISO ARNTL gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr 1:178,039,002...178,137,469
Ensembl chr 1:178,039,063...178,137,465
JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions ISO NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr11:72,577,547...72,619,435
Ensembl chr11:72,578,533...72,614,176
JBrowse link
G Bdh2 3-hydroxybutyrate dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 2:240,461,505...240,482,149
Ensembl chr 2:240,461,505...240,482,145
JBrowse link
G Casp3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr4 carbonyl reductase 4 multiple interactions ISO NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr16:31,944,328...31,972,553
Ensembl chr16:31,956,753...31,972,507
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions ISO CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr14:43,883,450...43,890,171
Ensembl chr14:43,883,458...43,890,171
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Cyb5b cytochrome b5 type B multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr19:39,357,814...39,391,680
Ensembl chr19:39,357,791...39,393,189
JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 affects binding
multiple interactions
ISO CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD PMID:16469290 PMID:25170804 NCBI chr 7:124,024,003...124,041,564
Ensembl chr 7:124,023,995...124,041,594
JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr10:109,906,119...109,909,696
Ensembl chr10:109,906,815...109,909,715
JBrowse link
G Dek DEK proto-oncogene increases oxidation ISO DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834
JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 3:55,623,671...55,645,883
Ensembl chr 3:55,623,634...55,648,325
JBrowse link
G Enox2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions ISO [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:135,918,938...136,303,267
Ensembl chr  X:135,918,929...136,303,249
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing
ISO ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD
CTD PMID:25440059 NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
JBrowse link
G Gale UDP-galactose-4-epimerase multiple interactions ISO NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:16,141,062...16,187,271
Ensembl chr18:16,146,447...16,185,496
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO
EXP
[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
CTD PMID:15788719 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance
multiple interactions
ISO GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]
CTD PMID:25246272 PMID:25536389 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase increases metabolic processing ISO HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 2:236,353,445...236,395,067
Ensembl chr 2:236,353,445...236,395,067
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Hpse heparanase increases expression EXP NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr14:10,534,358...10,576,686
Ensembl chr14:10,534,423...10,575,224
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions
EXP
ISO
HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]
CTD PMID:26859423 NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions ISO [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:21,696,796...21,699,241
Ensembl chr  X:21,696,772...21,699,241
JBrowse link
G Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 multiple interactions ISO NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr14:7,054,724...7,104,567
Ensembl chr14:7,073,445...7,104,566
JBrowse link
G Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 multiple interactions ISO NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr14:7,113,544...7,128,218
Ensembl chr14:7,113,544...7,128,218
JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 multiple interactions ISO NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr 1:101,541,266...101,551,059
Ensembl chr 1:101,541,266...101,551,059
JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions ISO NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640
JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 multiple interactions ISO NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr 7:2,412,370...2,431,249
Ensembl chr 7:2,412,363...2,431,197
Ensembl chr13:2,412,363...2,431,197
JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929
JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr 1:199,248,084...199,251,745
Ensembl chr 1:199,248,470...199,251,740
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]
CTD PMID:27469509 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression
multiple interactions
ISO NAD results in increased expression of IGFBP1 mRNA
NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
CTD PMID:32781018 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Insr insulin receptor multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
JBrowse link
G Ldha lactate dehydrogenase A increases oxidation EXP LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
JBrowse link
G LOC102552569 P2Y purinoceptor 11-like multiple interactions ISO P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 8:21,910,636...21,911,499 JBrowse link
G Mir34a microRNA 34a decreases abundance
multiple interactions
ISO MIR34A mRNA results in decreased abundance of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]
CTD PMID:23834033 NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr13:102,693,679...102,724,120
Ensembl chr13:102,698,546...102,721,218
JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 multiple interactions ISO [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr13:102,724,266...102,755,511
Ensembl chr13:102,724,348...102,756,174
JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming increases expression ISO NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr 1:214,663,929...214,693,197 JBrowse link
G Nadk NAD kinase increases phosphorylation ISO NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions ISO [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr 1:216,985,710...217,013,743
Ensembl chr 1:216,985,714...217,013,702
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions
ISO NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]
CTD PMID:23834033 PMID:25505128 NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 2:46,372,488...46,476,162
Ensembl chr 2:46,372,518...46,476,203
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases oxidation
multiple interactions
EXP NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
CTD PMID:27558805 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions ISO P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:151,314,818...151,320,312
Ensembl chr 2:151,314,818...151,320,319
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance
ISO
EXP
[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]
PARP1 protein affects the abundance of NAD
CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 PMID:25440059 PMID:25536389 PMID:27026705 PMID:27694308 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 decreases abundance ISO PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 7:117,291,592...117,300,878
Ensembl chr 7:117,291,877...117,300,662
JBrowse link
G Pla2g6 phospholipase A2 group VI multiple interactions ISO PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 7:120,519,479...120,559,716
Ensembl chr 7:120,519,467...120,559,347
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
decreases activity
EXP 3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] CTD PMID:18815186 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 5:140,538,260...140,558,163
Ensembl chr 5:140,538,260...140,558,162
JBrowse link
G Rdh10 retinol dehydrogenase 10 multiple interactions ISO NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 5:2,605,265...2,631,905
Ensembl chr 5:2,603,505...2,632,030
JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr 7:71,058,150...71,072,685
Ensembl chr 7:70,980,422...71,072,689
JBrowse link
G Rdh5 retinol dehydrogenase 5 multiple interactions ISO NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr 7:3,335,681...3,342,573
Ensembl chr 7:3,335,742...3,342,491
JBrowse link
G Sdr16c5 short chain dehydrogenase/reductase family 16C, member 5 affects activity
multiple interactions
ISO NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein
CTD PMID:18926804 PMID:25526675 NCBI chr 5:16,904,926...16,930,111
Ensembl chr 5:16,904,926...16,930,075
JBrowse link
G Sdr9c7 short chain dehydrogenase/reductase family 9C, member 7 multiple interactions ISO NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr 7:71,152,366...71,169,510
Ensembl chr 7:71,157,664...71,170,511
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance
ISO
EXP
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Smpd2 sphingomyelin phosphodiesterase 2 affects activity ISO NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr20:46,212,070...46,215,183
Ensembl chr20:46,211,892...46,215,120
JBrowse link
G Sphk1 sphingosine kinase 1 decreases activity ISO NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
JBrowse link
G Taldo1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr 1:214,375,555...214,385,886
Ensembl chr 1:214,375,515...214,385,885
JBrowse link
G Tgds TDP-glucose 4,6-dehydratase multiple interactions ISO NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr15:103,319,268...103,340,239
Ensembl chr15:103,319,268...103,340,240
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein
CTD PMID:10334203 PMID:11461765 PMID:12390773 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tyr tyrosinase multiple interactions
increases oxidation
ISO ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:11,165,006...11,240,329
Ensembl chr 9:11,164,715...11,339,790
JBrowse link
G Xrcc1 X-ray repair cross complementing 1 decreases reduction ISO XRCC1 gene mutant form results in decreased reduction of NAD CTD PMID:30998386 NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
JBrowse link
NAD(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acmsd aminocarboxymuconate semialdehyde decarboxylase increases abundance EXP ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr13:44,424,689...44,468,734
Ensembl chr13:44,424,689...44,468,734
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions
increases activity
ISO [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein
CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 multiple interactions ISO [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 5:61,382,351...61,387,359
Ensembl chr 5:61,382,351...61,387,358
JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance
ISO
EXP
[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD
CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 PMID:23295226 NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity
ISO [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein
CTD PMID:10856427 PMID:21256123 NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 multiple interactions EXP NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
JBrowse link
G Arntl aryl hydrocarbon receptor nuclear translocator-like decreases oxidation ISO ARNTL gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr 1:178,039,002...178,137,469
Ensembl chr 1:178,039,063...178,137,465
JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions ISO NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr11:72,577,547...72,619,435
Ensembl chr11:72,578,533...72,614,176
JBrowse link
G Bdh2 3-hydroxybutyrate dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 2:240,461,505...240,482,149
Ensembl chr 2:240,461,505...240,482,145
JBrowse link
G Casp3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr4 carbonyl reductase 4 multiple interactions ISO NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr16:31,944,328...31,972,553
Ensembl chr16:31,956,753...31,972,507
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions ISO CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr14:43,883,450...43,890,171
Ensembl chr14:43,883,458...43,890,171
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Cyb5b cytochrome b5 type B multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr19:39,357,814...39,391,680
Ensembl chr19:39,357,791...39,393,189
JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 affects binding
multiple interactions
ISO CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD PMID:16469290 PMID:25170804 NCBI chr 7:124,024,003...124,041,564
Ensembl chr 7:124,023,995...124,041,594
JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr10:109,906,119...109,909,696
Ensembl chr10:109,906,815...109,909,715
JBrowse link
G Dek DEK proto-oncogene increases oxidation ISO DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834
JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 3:55,623,671...55,645,883
Ensembl chr 3:55,623,634...55,648,325
JBrowse link
G Enox2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions ISO [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:135,918,938...136,303,267
Ensembl chr  X:135,918,929...136,303,249
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing
ISO ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD
CTD PMID:25440059 NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
JBrowse link
G Gale UDP-galactose-4-epimerase multiple interactions ISO NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:16,141,062...16,187,271
Ensembl chr18:16,146,447...16,185,496
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO
EXP
[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
CTD PMID:15788719 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance
multiple interactions
ISO GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]
CTD PMID:25246272 PMID:25536389 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase increases metabolic processing ISO HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 2:236,353,445...236,395,067
Ensembl chr 2:236,353,445...236,395,067
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Hpse heparanase increases expression EXP NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr14:10,534,358...10,576,686
Ensembl chr14:10,534,423...10,575,224
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions
EXP
ISO
HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]
CTD PMID:26859423 NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions ISO [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:21,696,796...21,699,241
Ensembl chr  X:21,696,772...21,699,241
JBrowse link
G Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 multiple interactions ISO NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr14:7,054,724...7,104,567
Ensembl chr14:7,073,445...7,104,566
JBrowse link
G Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 multiple interactions ISO NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr14:7,113,544...7,128,218
Ensembl chr14:7,113,544...7,128,218
JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 multiple interactions ISO NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr 1:101,541,266...101,551,059
Ensembl chr 1:101,541,266...101,551,059
JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions ISO NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640
JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 multiple interactions ISO NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr 7:2,412,370...2,431,249
Ensembl chr 7:2,412,363...2,431,197
Ensembl chr13:2,412,363...2,431,197
JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929
JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr 1:199,248,084...199,251,745
Ensembl chr 1:199,248,470...199,251,740
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]
CTD PMID:27469509 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions
increases expression
ISO NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
NAD results in increased expression of IGFBP1 mRNA
CTD PMID:32781018 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Insr insulin receptor multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
JBrowse link
G Ldha lactate dehydrogenase A increases oxidation EXP LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
JBrowse link
G LOC102552569 P2Y purinoceptor 11-like multiple interactions ISO P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 8:21,910,636...21,911,499 JBrowse link
G Mir34a microRNA 34a multiple interactions
decreases abundance
ISO [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] CTD PMID:23834033 NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr13:102,693,679...102,724,120
Ensembl chr13:102,698,546...102,721,218
JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 multiple interactions ISO [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr13:102,724,266...102,755,511
Ensembl chr13:102,724,348...102,756,174
JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming increases expression ISO NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr 1:214,663,929...214,693,197 JBrowse link
G Nadk NAD kinase increases phosphorylation ISO NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions ISO [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr 1:216,985,710...217,013,743
Ensembl chr 1:216,985,714...217,013,702
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions
ISO NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]
CTD PMID:23834033 PMID:25505128 NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 2:46,372,488...46,476,162
Ensembl chr 2:46,372,518...46,476,203
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases oxidation
multiple interactions
EXP NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
CTD PMID:27558805 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions ISO P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:151,314,818...151,320,312
Ensembl chr 2:151,314,818...151,320,319
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance
ISO
EXP
[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
PARP1 protein results in decreased abundance of NAD
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]
PARP1 protein affects the abundance of NAD
CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 PMID:25440059 PMID:25536389 PMID:27026705 PMID:27694308 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 decreases abundance ISO PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 7:117,291,592...117,300,878
Ensembl chr 7:117,291,877...117,300,662
JBrowse link
G Pla2g6 phospholipase A2 group VI multiple interactions ISO PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 7:120,519,479...120,559,716
Ensembl chr 7:120,519,467...120,559,347
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases activity
multiple interactions
EXP NAD results in decreased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein]
CTD PMID:18815186 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 5:140,538,260...140,558,163
Ensembl chr 5:140,538,260...140,558,162
JBrowse link
G Rdh10 retinol dehydrogenase 10 multiple interactions ISO NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 5:2,605,265...2,631,905
Ensembl chr 5:2,603,505...2,632,030
JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr 7:71,058,150...71,072,685
Ensembl chr 7:70,980,422...71,072,689
JBrowse link
G Rdh5 retinol dehydrogenase 5 multiple interactions ISO NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr 7:3,335,681...3,342,573
Ensembl chr 7:3,335,742...3,342,491
JBrowse link
G Sdr16c5 short chain dehydrogenase/reductase family 16C, member 5 affects activity
multiple interactions
ISO NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein
CTD PMID:18926804 PMID:25526675 NCBI chr 5:16,904,926...16,930,111
Ensembl chr 5:16,904,926...16,930,075
JBrowse link
G Sdr9c7 short chain dehydrogenase/reductase family 9C, member 7 multiple interactions ISO NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr 7:71,152,366...71,169,510
Ensembl chr 7:71,157,664...71,170,511
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance
ISO
EXP
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Smpd2 sphingomyelin phosphodiesterase 2 affects activity ISO NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr20:46,212,070...46,215,183
Ensembl chr20:46,211,892...46,215,120
JBrowse link
G Sphk1 sphingosine kinase 1 decreases activity ISO NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
JBrowse link
G Taldo1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr 1:214,375,555...214,385,886
Ensembl chr 1:214,375,515...214,385,885
JBrowse link
G Tgds TDP-glucose 4,6-dehydratase multiple interactions ISO NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr15:103,319,268...103,340,239
Ensembl chr15:103,319,268...103,340,240
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein
CTD PMID:10334203 PMID:11461765 PMID:12390773 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tyr tyrosinase multiple interactions
increases oxidation
ISO ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:11,165,006...11,240,329
Ensembl chr 9:11,164,715...11,339,790
JBrowse link
G Xrcc1 X-ray repair cross complementing 1 decreases reduction ISO XRCC1 gene mutant form results in decreased reduction of NAD CTD PMID:30998386 NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
JBrowse link
NADP zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase multiple interactions EXP [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B multiple interactions
increases activity
affects binding
ISO [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B1 protein
NADP binds to AKR1B1 protein binds to fidarestat
CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction
ISO [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP
CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 multiple interactions EXP [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-Butanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-hexanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-indanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-nonanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Benzyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of n-decyl alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Nicotinyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the reduction of 1-phenyl-1,2-propanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 16-ketoestrone; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-hexanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-pentanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-decadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-hexenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 21-dehydrocortisol; [AKR1B8 protein co-treated with NADP] affects the reduction of 3-deoxyglucosone; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-nitrobenzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Acrolein; [AKR1B8 protein co-treated with NADP] affects the reduction of benzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of butyraldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Diacetyl; [AKR1B8 protein co-treated with NADP] affects the reduction of glycolaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Glyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Isatin; [AKR1B8 protein co-treated with NADP] affects the reduction of Phenylglyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Pyruvaldehyde CTD PMID:18845131 NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C4 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C4 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP inhibits the reaction [AKR1C4 protein results in increased oxidation of Hydroxysteroids] CTD PMID:14672942 PMID:21910479 NCBI chr17:69,441,253...69,460,334
Ensembl chr17:69,441,223...69,460,321
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 4:65,110,706...65,143,930
Ensembl chr 4:65,110,746...65,143,941
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity
ISO [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein
CTD PMID:10856427 PMID:21256123 NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
JBrowse link
G Atg5 autophagy related 5 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Bche butyrylcholinesterase multiple interactions ISO [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
JBrowse link
G Becn1 beclin 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Cat catalase multiple interactions EXP CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions ISO NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Ctsb cathepsin B multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Ctsd cathepsin D multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions ISO [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO
EXP
NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein
CTD PMID:15720144 PMID:24713513 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 multiple interactions ISO [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr 1:83,711,223...83,725,222
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 multiple interactions EXP [CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr 1:83,744,229...83,766,490
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B1 protein CTD PMID:11805216 PMID:16485904 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 multiple interactions ISO [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp2d2 cytochrome P450, family 2, subfamily d, polypeptide 2 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 7:123,651,827...123,655,896
Ensembl chr 7:123,651,827...123,655,896
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions ISO [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO
EXP
[vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein
CTD PMID:11181492 PMID:24713513 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 multiple interactions ISO NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP3A62 protein CTD PMID:24713513 NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr10:109,906,119...109,909,696
Ensembl chr10:109,906,815...109,909,715
JBrowse link
G Decr1 2,4-dienoyl-CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 5:29,573,893...29,601,731
Ensembl chr 5:29,573,898...29,601,748
JBrowse link
G Decr2 2,4-dienoyl-CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr10:15,451,850...15,460,227
Ensembl chr10:15,431,638...15,465,413
JBrowse link
G Dhfr dihydrofolate reductase decreases activity ISO NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
JBrowse link
G Dhrs1 dehydrogenase/reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr15:34,424,017...34,431,302
Ensembl chr15:34,424,016...34,431,325
JBrowse link
G Dhrs11 dehydrogenase/reductase 11 multiple interactions ISO NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr10:72,144,042...72,153,496
Ensembl chr10:72,144,042...72,153,375
JBrowse link
G Dhrs13 dehydrogenase/reductase 13 multiple interactions ISO NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr10:65,329,407...65,334,533
Ensembl chr10:65,329,940...65,334,500
JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions ISO [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr15:33,876,701...33,891,559
Ensembl chr15:33,885,106...33,891,539
JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions
increases activity
ISO NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein
CTD PMID:25451588 PMID:25526675 NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383
JBrowse link
G Dhrs4 dehydrogenase/reductase 4 multiple interactions ISO NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr15:34,155,043...34,167,073
Ensembl chr15:34,155,504...34,167,072
JBrowse link
G Dhrs7 dehydrogenase/reductase 7 multiple interactions ISO NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr 6:95,522,577...95,541,393
Ensembl chr 6:95,522,577...95,541,393
JBrowse link
G Dhrs7b dehydrogenase/reductase 7B multiple interactions ISO NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr10:47,065,755...47,111,089
Ensembl chr10:47,065,850...47,111,101
JBrowse link
G Dhrs7c dehydrogenase/reductase 7C multiple interactions ISO NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr10:54,352,270...54,370,653
Ensembl chr10:54,352,270...54,370,653
JBrowse link
G Far1 fatty acyl CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr 1:178,351,674...178,412,838
Ensembl chr 1:178,351,680...178,431,395
JBrowse link
G Far2 fatty acyl CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr 4:182,446,400...182,563,485
Ensembl chr 4:182,483,194...182,565,436
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO
EXP
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]
CTD PMID:20369854 NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases reduction
increases expression
ISO
EXP
G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein
CTD PMID:1922005 PMID:5432368 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gfus GDP-L-fucose synthase multiple interactions ISO NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 7:116,958,427...116,963,281
Ensembl chr 7:116,958,392...116,963,295
JBrowse link
G Glud1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr16:10,661,486...10,695,557
Ensembl chr16:10,662,021...10,695,557
JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase multiple interactions ISO NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr17:33,408,722...33,938,086
Ensembl chr17:33,408,722...33,938,085
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance ISO GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
increases oxidation
ISO
EXP
NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]
CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation
ISO
EXP
NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]
CTD PMID:25526675 PMID:26859423 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions ISO NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions ISO [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr10:88,987,558...88,989,758
Ensembl chr10:88,987,558...88,989,757
JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr 3:82,924,699...83,048,465
Ensembl chr 3:82,924,687...83,048,435
JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP
ISO
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein
CTD PMID:20522127 PMID:25526675 NCBI chr17:1,579,319...1,610,745
Ensembl chr17:1,579,319...1,610,745
JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 multiple interactions ISO NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr13:88,288,116...88,308,019
Ensembl chr13:88,288,046...88,307,988
JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675
G Hsdl1 hydroxysteroid dehydrogenase like 1 multiple interactions ISO NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr19:52,209,403...52,225,486
Ensembl chr19:52,210,859...52,217,728
JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 5:76,812,881...76,848,853
Ensembl chr 5:76,812,931...76,848,101
JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 multiple interactions ISO NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of NADP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]
CTD PMID:27469509 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Iyd iodotyrosine deiodinase increases oxidation ISO IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 1:40,086,513...40,100,966
Ensembl chr 1:40,086,470...40,101,840
JBrowse link
G Kcnab2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions
EXP NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite
CTD PMID:19013139 PMID:21296056 NCBI chr 5:169,570,327...169,658,875
Ensembl chr 5:169,572,517...169,658,875
JBrowse link
G Kdsr 3-ketodihydrosphingosine reductase multiple interactions ISO NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr13:26,779,386...26,812,271
Ensembl chr13:26,780,633...26,812,215
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr16:81,689,576...81,714,341
Ensembl chr16:81,689,335...81,714,419
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mat2b methionine adenosyltransferase 2B multiple interactions ISO [Resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr10:25,832,096...25,848,045
Ensembl chr10:25,832,072...25,847,994
JBrowse link
G Nadk NAD kinase multiple interactions ISO [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects abundance
affects oxidation
ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP
CTD PMID:21775727 PMID:29950142 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nmral1 NmrA like redox sensor 1 multiple interactions ISO [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr10:11,045,924...11,055,154
Ensembl chr10:11,046,024...11,055,158
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO
EXP
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nsdhl NAD(P) dependent steroid dehydrogenase-like multiple interactions ISO NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:152,933,118...152,964,399
Ensembl chr  X:152,933,069...152,964,390
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 9:79,601,937...79,630,547
Ensembl chr 9:79,601,901...79,630,536
JBrowse link
G Pgd phosphogluconate dehydrogenase increases expression EXP NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 5:165,966,128...165,982,327 JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing
EXP
ISO
NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 PMID:24120545 PMID:27558805 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Ppif peptidylprolyl isomerase F multiple interactions EXP [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr16:1,979,191...1,985,912
Ensembl chr16:1,979,191...1,985,908
JBrowse link
G Prnp prion protein multiple interactions ISO [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]
CTD PMID:16990274 PMID:19149680 NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions EXP [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamic aldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
G Qdpr quinoid dihydropteridine reductase multiple interactions ISO NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr14:70,164,682...70,178,284
Ensembl chr14:70,164,650...70,178,284
JBrowse link
G Rdh11 retinol dehydrogenase 11 multiple interactions ISO NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr 6:102,356,498...102,372,618
Ensembl chr 6:102,356,492...102,372,611
JBrowse link
G Rdh12 retinol dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr 6:102,392,828...102,405,750
Ensembl chr 6:102,392,828...102,405,750
JBrowse link
G Rdh13 retinol dehydrogenase 13 multiple interactions ISO NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr 1:72,956,017...72,983,811
Ensembl chr 1:72,956,026...72,984,350
JBrowse link
G Rdh14 retinol dehydrogenase 14 multiple interactions ISO NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 6:36,106,926...36,112,069
Ensembl chr 6:36,107,147...36,112,064
JBrowse link
G Rdh8 retinol dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr 8:21,835,065...21,842,374
Ensembl chr 8:21,835,103...21,842,374
JBrowse link
G Sdr39u1 short chain dehydrogenase/reductase family 39U, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr15:34,563,786...34,567,465
Ensembl chr15:34,563,786...34,566,719
JBrowse link
G Sdr42e1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr19:50,207,960...50,220,455
Ensembl chr19:50,207,980...50,220,455
JBrowse link
G Spr sepiapterin reductase multiple interactions ISO NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 4:116,912,343...116,916,073
Ensembl chr 4:116,912,351...116,916,236
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
JBrowse link
G Taldo1 transaldolase 1 decreases abundance
multiple interactions
ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]
CTD PMID:19436114 NCBI chr 1:214,375,555...214,385,886
Ensembl chr 1:214,375,515...214,385,885
JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase affects abundance EXP TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
JBrowse link
G Tigar TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance
EXP
ISO
NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
TIGAR protein results in increased abundance of NADP
CTD PMID:32057834 PMID:33359019 NCBI chr 4:159,635,145...159,654,108
Ensembl chr 4:159,635,153...159,654,063
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases reduction
ISO
EXP
[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [arsenic trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 PMID:24274902 PMID:26975474 NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
JBrowse link
G Wwox WW domain-containing oxidoreductase multiple interactions ISO NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr19:46,761,353...47,695,247 JBrowse link
NADP(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase multiple interactions EXP [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B multiple interactions
increases activity
affects binding
ISO [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B1 protein
NADP binds to AKR1B1 protein binds to fidarestat
CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction
ISO [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP
CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 multiple interactions EXP [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-Butanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-hexanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-indanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-nonanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Benzyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of n-decyl alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Nicotinyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the reduction of 1-phenyl-1,2-propanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 16-ketoestrone; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-hexanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-pentanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-decadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-hexenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 21-dehydrocortisol; [AKR1B8 protein co-treated with NADP] affects the reduction of 3-deoxyglucosone; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-nitrobenzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Acrolein; [AKR1B8 protein co-treated with NADP] affects the reduction of benzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of butyraldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Diacetyl; [AKR1B8 protein co-treated with NADP] affects the reduction of glycolaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Glyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Isatin; [AKR1B8 protein co-treated with NADP] affects the reduction of Phenylglyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Pyruvaldehyde CTD PMID:18845131 NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C4 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C4 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP inhibits the reaction [AKR1C4 protein results in increased oxidation of Hydroxysteroids] CTD PMID:14672942 PMID:21910479 NCBI chr17:69,441,253...69,460,334
Ensembl chr17:69,441,223...69,460,321
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 4:65,110,706...65,143,930
Ensembl chr 4:65,110,746...65,143,941
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity
ISO [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein
CTD PMID:10856427 PMID:21256123 NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
JBrowse link
G Atg5 autophagy related 5 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Bche butyrylcholinesterase multiple interactions ISO [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
JBrowse link
G Becn1 beclin 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Cat catalase multiple interactions EXP CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions ISO NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Ctsb cathepsin B multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Ctsd cathepsin D multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions ISO [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO
EXP
NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein
CTD PMID:15720144 PMID:24713513 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 multiple interactions ISO [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr 1:83,711,223...83,725,222
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 multiple interactions EXP [CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr 1:83,744,229...83,766,490
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B1 protein CTD PMID:11805216 PMID:16485904 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 multiple interactions ISO [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp2d2 cytochrome P450, family 2, subfamily d, polypeptide 2 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 7:123,651,827...123,655,896
Ensembl chr 7:123,651,827...123,655,896
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions ISO [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO
EXP
[vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein
CTD PMID:11181492 PMID:24713513 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 multiple interactions ISO NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP3A62 protein CTD PMID:24713513 NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr10:109,906,119...109,909,696
Ensembl chr10:109,906,815...109,909,715
JBrowse link
G Decr1 2,4-dienoyl-CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 5:29,573,893...29,601,731
Ensembl chr 5:29,573,898...29,601,748
JBrowse link
G Decr2 2,4-dienoyl-CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr10:15,451,850...15,460,227
Ensembl chr10:15,431,638...15,465,413
JBrowse link
G Dhfr dihydrofolate reductase decreases activity ISO NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
JBrowse link
G Dhrs1 dehydrogenase/reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr15:34,424,017...34,431,302
Ensembl chr15:34,424,016...34,431,325
JBrowse link
G Dhrs11 dehydrogenase/reductase 11 multiple interactions ISO NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr10:72,144,042...72,153,496
Ensembl chr10:72,144,042...72,153,375
JBrowse link
G Dhrs13 dehydrogenase/reductase 13 multiple interactions ISO NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr10:65,329,407...65,334,533
Ensembl chr10:65,329,940...65,334,500
JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions ISO [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr15:33,876,701...33,891,559
Ensembl chr15:33,885,106...33,891,539
JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions
increases activity
ISO NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein
CTD PMID:25451588 PMID:25526675 NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383
JBrowse link
G Dhrs4 dehydrogenase/reductase 4 multiple interactions ISO NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr15:34,155,043...34,167,073
Ensembl chr15:34,155,504...34,167,072
JBrowse link
G Dhrs7 dehydrogenase/reductase 7 multiple interactions ISO NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr 6:95,522,577...95,541,393
Ensembl chr 6:95,522,577...95,541,393
JBrowse link
G Dhrs7b dehydrogenase/reductase 7B multiple interactions ISO NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr10:47,065,755...47,111,089
Ensembl chr10:47,065,850...47,111,101
JBrowse link
G Dhrs7c dehydrogenase/reductase 7C multiple interactions ISO NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr10:54,352,270...54,370,653
Ensembl chr10:54,352,270...54,370,653
JBrowse link
G Far1 fatty acyl CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr 1:178,351,674...178,412,838
Ensembl chr 1:178,351,680...178,431,395
JBrowse link
G Far2 fatty acyl CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr 4:182,446,400...182,563,485
Ensembl chr 4:182,483,194...182,565,436
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO
EXP
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]
CTD PMID:20369854 NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases reduction
increases expression
ISO
EXP
G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein
CTD PMID:1922005 PMID:5432368 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gfus GDP-L-fucose synthase multiple interactions ISO NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 7:116,958,427...116,963,281
Ensembl chr 7:116,958,392...116,963,295
JBrowse link
G Glud1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr16:10,661,486...10,695,557
Ensembl chr16:10,662,021...10,695,557
JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase multiple interactions ISO NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr17:33,408,722...33,938,086
Ensembl chr17:33,408,722...33,938,085
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance ISO GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
increases oxidation
ISO
EXP
NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]
CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation
ISO
EXP
NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]
CTD PMID:25526675 PMID:26859423 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions ISO NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions ISO [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr10:88,987,558...88,989,758
Ensembl chr10:88,987,558...88,989,757
JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr 3:82,924,699...83,048,465
Ensembl chr 3:82,924,687...83,048,435
JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP
ISO
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein
CTD PMID:20522127 PMID:25526675 NCBI chr17:1,579,319...1,610,745
Ensembl chr17:1,579,319...1,610,745
JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 multiple interactions ISO NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr13:88,288,116...88,308,019
Ensembl chr13:88,288,046...88,307,988
JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675
G Hsdl1 hydroxysteroid dehydrogenase like 1 multiple interactions ISO NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr19:52,209,403...52,225,486
Ensembl chr19:52,210,859...52,217,728
JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 5:76,812,881...76,848,853
Ensembl chr 5:76,812,931...76,848,101
JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 multiple interactions ISO NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of NADP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]
CTD PMID:27469509 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Iyd iodotyrosine deiodinase increases oxidation ISO IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 1:40,086,513...40,100,966
Ensembl chr 1:40,086,470...40,101,840
JBrowse link
G Kcnab2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions
EXP NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite
CTD PMID:19013139 PMID:21296056 NCBI chr 5:169,570,327...169,658,875
Ensembl chr 5:169,572,517...169,658,875
JBrowse link
G Kdsr 3-ketodihydrosphingosine reductase multiple interactions ISO NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr13:26,779,386...26,812,271
Ensembl chr13:26,780,633...26,812,215
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr16:81,689,576...81,714,341
Ensembl chr16:81,689,335...81,714,419
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mat2b methionine adenosyltransferase 2B multiple interactions ISO [resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr10:25,832,096...25,848,045
Ensembl chr10:25,832,072...25,847,994
JBrowse link
G Nadk NAD kinase multiple interactions ISO [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects abundance
affects oxidation
ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP
CTD PMID:21775727 PMID:29950142 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nmral1 NmrA like redox sensor 1 multiple interactions ISO [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr10:11,045,924...11,055,154
Ensembl chr10:11,046,024...11,055,158
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO
EXP
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nsdhl NAD(P) dependent steroid dehydrogenase-like multiple interactions ISO NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:152,933,118...152,964,399
Ensembl chr  X:152,933,069...152,964,390
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 9:79,601,937...79,630,547
Ensembl chr 9:79,601,901...79,630,536
JBrowse link
G Pgd phosphogluconate dehydrogenase increases expression EXP NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 5:165,966,128...165,982,327 JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing
EXP
ISO
NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 PMID:24120545 PMID:27558805 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Ppif peptidylprolyl isomerase F multiple interactions EXP [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr16:1,979,191...1,985,912
Ensembl chr16:1,979,191...1,985,908
JBrowse link
G Prnp prion protein multiple interactions ISO [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]
CTD PMID:16990274 PMID:19149680 NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions EXP [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamic aldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
G Qdpr quinoid dihydropteridine reductase multiple interactions ISO NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr14:70,164,682...70,178,284
Ensembl chr14:70,164,650...70,178,284
JBrowse link
G Rdh11 retinol dehydrogenase 11 multiple interactions ISO NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr 6:102,356,498...102,372,618
Ensembl chr 6:102,356,492...102,372,611
JBrowse link
G Rdh12 retinol dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr 6:102,392,828...102,405,750
Ensembl chr 6:102,392,828...102,405,750
JBrowse link
G Rdh13 retinol dehydrogenase 13 multiple interactions ISO NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr 1:72,956,017...72,983,811
Ensembl chr 1:72,956,026...72,984,350
JBrowse link
G Rdh14 retinol dehydrogenase 14 multiple interactions ISO NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 6:36,106,926...36,112,069
Ensembl chr 6:36,107,147...36,112,064
JBrowse link
G Rdh8 retinol dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr 8:21,835,065...21,842,374
Ensembl chr 8:21,835,103...21,842,374
JBrowse link
G Sdr39u1 short chain dehydrogenase/reductase family 39U, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr15:34,563,786...34,567,465
Ensembl chr15:34,563,786...34,566,719
JBrowse link
G Sdr42e1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr19:50,207,960...50,220,455
Ensembl chr19:50,207,980...50,220,455
JBrowse link
G Spr sepiapterin reductase multiple interactions ISO NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 4:116,912,343...116,916,073
Ensembl chr 4:116,912,351...116,916,236
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
JBrowse link
G Taldo1 transaldolase 1 decreases abundance
multiple interactions
ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]
CTD PMID:19436114 NCBI chr 1:214,375,555...214,385,886
Ensembl chr 1:214,375,515...214,385,885
JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase affects abundance EXP TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
JBrowse link
G Tigar TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance
EXP
ISO
NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
TIGAR protein results in increased abundance of NADP
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
CTD PMID:32057834 PMID:33359019 NCBI chr 4:159,635,145...159,654,108
Ensembl chr 4:159,635,153...159,654,063
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases reduction
ISO
EXP
[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [Arsenic Trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 PMID:24274902 PMID:26975474 NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
JBrowse link
G Wwox WW domain-containing oxidoreductase multiple interactions ISO NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr19:46,761,353...47,695,247 JBrowse link
nicotinic acid-adenine dinucleotide phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Edn1 endothelin 1 increases metabolic processing
multiple interactions
ISO EDN1 protein results in increased metabolism of NAADP
NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP]
CTD PMID:23940720 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Faslg Fas ligand multiple interactions
increases abundance
ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Mcoln1 mucolipin TRP cation channel 1 increases activity
multiple interactions
ISO NAADP results in increased activity of MCOLN1 protein
[NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium
CTD PMID:21613607 NCBI chr12:2,054,629...2,068,682
Ensembl chr12:2,054,680...2,068,682
JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions ISO NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP] CTD PMID:23940720 NCBI chr  X:104,909,328...104,932,508
Ensembl chr  X:104,909,326...104,932,508
JBrowse link
P(1),P(4)-bis(5'-adenosyl) tetraphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 multiple interactions EXP diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein] CTD PMID:19442829 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Nudt10 nudix hydrolase 10 increases metabolic processing ISO NUDT10 protein results in increased metabolism of diadenosine tetraphosphate CTD PMID:12121577 NCBI chr  X:17,540,036...17,541,296
Ensembl chr  X:17,540,458...17,540,952
Ensembl chr  X:17,540,458...17,540,952
JBrowse link
G Nudt2 nudix hydrolase 2 increases hydrolysis ISO NUDT2 protein results in increased hydrolysis of diadenosine tetraphosphate CTD PMID:20533549 NCBI chr 5:57,845,819...57,860,658
Ensembl chr 5:57,845,819...57,860,658
JBrowse link
G Th tyrosine hydroxylase multiple interactions EXP diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in decreased expression of TH protein] CTD PMID:19442829 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
JBrowse link
P(1),P(5)-bis(5'-adenosyl) pentaphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cftr CF transmembrane conductance regulator multiple interactions ISO P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] CTD PMID:15684079 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
G Nudt10 nudix hydrolase 10 increases metabolic processing
multiple interactions
ISO NUDT10 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate
[NUDT10 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of adenosine 5'-tetraphosphate; [NUDT10 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; manganese chloride promotes the reaction [NUDT10 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate]
CTD PMID:12121577 NCBI chr  X:17,540,036...17,541,296
Ensembl chr  X:17,540,458...17,540,952
Ensembl chr  X:17,540,458...17,540,952
JBrowse link
G Nudt11 nudix hydrolase 11 multiple interactions
increases metabolic processing
ISO [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of adenosine 5'-tetraphosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; manganese chloride promotes the reaction [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] CTD PMID:12121577 NCBI chr  X:17,171,510...17,215,108
Ensembl chr  X:17,540,458...17,540,952
Ensembl chr  X:17,540,458...17,540,952
JBrowse link
G Sirt1 sirtuin 1 multiple interactions EXP P(1),P(5)-di(adenosine-5'-)pentaphosphate analog inhibits the reaction [[Nitrites co-treated with Oxygen deficiency] results in increased expression of SIRT1 mRNA] CTD PMID:22892143 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
P(1),P(6)-bis(5'-adenosyl)hexaphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nudt10 nudix hydrolase 10 multiple interactions
increases metabolic processing
ISO [NUDT10 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate; [NUDT10 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate CTD PMID:12121577 NCBI chr  X:17,540,036...17,541,296
Ensembl chr  X:17,540,458...17,540,952
Ensembl chr  X:17,540,458...17,540,952
JBrowse link
G Nudt11 nudix hydrolase 11 multiple interactions
increases metabolic processing
ISO [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate; [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate CTD PMID:12121577 NCBI chr  X:17,171,510...17,215,108
Ensembl chr  X:17,540,458...17,540,952
Ensembl chr  X:17,540,458...17,540,952
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19773
    role 19719
      application 19403
        solvent 16547
          phosphoric acid 7960
            phosphoric acid derivative 7640
              organic phosphate 7639
                nucleoside phosphate 1727
                  nucleotide 1726
                    dinucleotide 198
                      (2'->5')-dinucleotide + 0
                      (3'->5')-dinucleotide + 0
                      5'-pApG-3'(3-) 0
                      AcNADH 0
                      adenosin-5'-yl (2R,3S,4S)-5-[(3R,3aS,7aR)-10,11-dimethyl-1,4,6-trioxo-3-phenyl-2,3,5,6,7,7a-hexahydro-1H-benzo[g]pyrrolo[2,1-e]pteridin-8(4H)-yl]-2,3,4-trihydroxypentyl dihydrogen diphosphate 0
                      adenosin-5'-yl [(2R,3R,4R,5R)-5-(adenin-9-yl)-3-hydroxy-4-(phosphonooxy)tetrahydrofuran-2-yl]methyl dihydrogen diphosphate 0
                      diadenosyl polyphosphate + 7
                      flavin adenine dinucleotide + 3
                      molybdopterin dinucleotide + 0
                      nicotinamide dinucleotide + 190
                      nicotinic acid dinucleotide + 94
Path 2
Term Annotations click to browse term
  CHEBI ontology 19773
    subatomic particle 19772
      composite particle 19772
        hadron 19772
          baryon 19772
            nucleon 19772
              atomic nucleus 19772
                atom 19772
                  main group element atom 19662
                    p-block element atom 19662
                      chalcogen 19393
                        oxygen atom 19356
                          oxygen molecular entity 19356
                            hydroxides 19083
                              oxoacid 18310
                                pnictogen oxoacid 10315
                                  phosphorus oxoacid 9240
                                    phosphoric acids 7960
                                      phosphoric acid 7960
                                        phosphoric acid derivative 7640
                                          phosphate 7640
                                            organic phosphate 7639
                                              nucleoside phosphate 1727
                                                nucleotide 1726
                                                  dinucleotide 198
                                                    (2'->5')-dinucleotide + 0
                                                    (3'->5')-dinucleotide + 0
                                                    5'-pApG-3'(3-) 0
                                                    AcNADH 0
                                                    adenosin-5'-yl (2R,3S,4S)-5-[(3R,3aS,7aR)-10,11-dimethyl-1,4,6-trioxo-3-phenyl-2,3,5,6,7,7a-hexahydro-1H-benzo[g]pyrrolo[2,1-e]pteridin-8(4H)-yl]-2,3,4-trihydroxypentyl dihydrogen diphosphate 0
                                                    adenosin-5'-yl [(2R,3R,4R,5R)-5-(adenin-9-yl)-3-hydroxy-4-(phosphonooxy)tetrahydrofuran-2-yl]methyl dihydrogen diphosphate 0
                                                    diadenosyl polyphosphate + 7
                                                    flavin adenine dinucleotide + 3
                                                    molybdopterin dinucleotide + 0
                                                    nicotinamide dinucleotide + 190
                                                    nicotinic acid dinucleotide + 94
paths to the root